| For: | Zhou ML, Xu RN, Tan C, Zhang Z, Wan JF. Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report. World J Gastrointest Oncol 2023; 15(6): 1096-1104 [PMID: 37389115 DOI: 10.4251/wjgo.v15.i6.1096] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i6/1096.htm |
| Number | Citing Articles |
| 1 |
Mimi Xu, Yafei Zhang, Kui Zhao, Haiping Jiang, Guangfa Wang, Yan Wu, Yu Wang, Nian Liu, Xinhui Su. Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatment 18F-FDG PET imaging biomarkers in patients with locally advanced gastric cancer. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-13765-1
|
| 2 |
Fuping Gao, Xiaohua Zhou, Jin Wei, Qiong Sun, Jiapeng Wang, Qing Li. Expression characteristics and biological functions of CGB5 gene in gastric cancer. Acta Histochemica 2025; 127(2) doi: 10.1016/j.acthis.2025.152254
|
| 3 |
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa. Oligoprogression in Advanced Gastric and Gastroesophageal Junction Cancer: Integrating Local Therapy, Systemic Treatment Continuation, and Biomarker Reassessment. Journal of Gastrointestinal Cancer 2026; 57(1) doi: 10.1007/s12029-026-01549-0
|
| 4 |
Dongfeng Song, Yajie Rong, Yining Fu, Yan You, Wenze Wang, Xiaoyuan Li, Xiaolei Gong, Zhiyang Zhang, Yuping Ge, Xiang Wang, Lin Zhao, Chunmei Bai, Yi Ba. Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study. Annals of Surgical Oncology 2026; doi: 10.1245/s10434-026-20322-y
|
| 5 |
Huizi Li, Jiaobao Huang, Kuntang Liu, Jibiao Liu, Queling Liu, Zhiyong Zhou, Zhen Zong, Shengxun Mao. ChatGPT-4o outperforms gemini advanced in assisting multidisciplinary decision-making for advanced gastric cancer. European Journal of Surgical Oncology 2025; 51(8) doi: 10.1016/j.ejso.2025.110096
|